Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC

Josep M. Llovet, MD, PhD
Published: Monday, Aug 05, 2019



Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma (HCC).

In patients with HCC, Child-Pugh B stands for a classification that defines the status of liver failure, Llovet explains.

Prior to this trial, the actions and mechanisms of namodenoson in patients with Child-Pugh B HCC were unknown because all the drugs had been tested in Child-Pugh A patients, according to Llovet. As a result, patients who have Child-Pugh B HCC do not have a standard frontline therapy. Most of the TKIs are toxic in these patients, Llovet explains. Namodenoson has a tolerable safety profile, according to Llovet, and the drug is only being used on Child-Pugh B patients with more preserved liver function.

Results showed that the median overall survival was 4.1 months with namodenoson and 4.3 months in placebo in the intent-to-treat population. Moreover, the median progression-free survival was 2.6 months with namodenoson and 1.9 months with placebo.
SELECTED
LANGUAGE


Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma (HCC).

In patients with HCC, Child-Pugh B stands for a classification that defines the status of liver failure, Llovet explains.

Prior to this trial, the actions and mechanisms of namodenoson in patients with Child-Pugh B HCC were unknown because all the drugs had been tested in Child-Pugh A patients, according to Llovet. As a result, patients who have Child-Pugh B HCC do not have a standard frontline therapy. Most of the TKIs are toxic in these patients, Llovet explains. Namodenoson has a tolerable safety profile, according to Llovet, and the drug is only being used on Child-Pugh B patients with more preserved liver function.

Results showed that the median overall survival was 4.1 months with namodenoson and 4.3 months in placebo in the intent-to-treat population. Moreover, the median progression-free survival was 2.6 months with namodenoson and 1.9 months with placebo.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x